A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Latest Information Update: 29 Apr 2025
At a glance
- Drugs LY 4052031 (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms NEXUS-01
- Sponsors Eli Lilly and Company
Most Recent Events
- 24 Apr 2025 Status changed from recruiting to suspended. Reason the study was stopped: The study was paused due to sponsor decision.
- 29 Jan 2025 Planned number of patients changed from 220 to 420.
- 25 Oct 2024 Trial Design presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.